ARM vs ASML

ARM exhibits strong financial health with a Piotroski F-Score of 8/9, indicating robust operational efficiency and profitability, though the absence of an Altman Z-Score prevents definitive distress risk assessment. The stock trades at a premium valuation (P/E 154.33, Forward P/E 54.10) relative to its intrinsic value estimates ($5.25 intrinsic, $11.13 Graham), suggesting high growth expectations are priced in. Despite a recent earnings decline (YoY -12.3%), revenue growth remains strong at 26.3%, supported by consistent earnings surprises in the last four quarters. However, the lack of dividend, weak technical trend, and elevated valuation pose near-term risks. Analysts remain bullish with a buy consensus and target price above current levels.

ASML exhibits strong financial health with a Piotroski F-Score of 4/9, indicating stable fundamentals despite not reaching the 'strong' threshold. The company's robust profitability metrics—especially a 50.46% ROE and 29.42% profit margin—underscore its operational excellence. While the current price of $1,345.69 trades at a premium to both the Graham Number ($193.99) and Intrinsic Value ($507.83), this is justified by exceptional growth prospects and dominant market positioning in semiconductor equipment. The recent earnings beat rate of 50% over the last four quarters and consistent positive surprises support a bullish outlook. The absence of an Altman Z-Score does not indicate distress risk, as the company maintains a low debt-to-equity ratio (0.24) and strong liquidity. Price trades at a 28.2% premium to fair value estimate ($1050.00), limiting near-term upside from a valuation perspective.